Better Times Ahead For Edwards Lifesciences Corp (NYSE: EW)?

Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $70.46, with 7.15 million shares of worth about $504.05 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.27% during that period and on April 23, 2025 the price saw a loss of about -0.20%. Currently the company’s common shares owned by public are about 588.60M shares, out of which, 574.31M shares are available for trading.

Stock saw a price change of -0.42% in past 5 days and over the past one month there was a price change of -1.25%. Year-to-date (YTD), EW shares are showing a performance of -4.82% which decreased to -18.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $95.25 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.65 million.

Edwards Lifesciences Corp (NYSE: EW) currently have 588.60M outstanding shares and institutions hold larger chunk of about 87.31% of that.

The stock has a current market capitalization of $41.27B and its 3Y-monthly beta is at 1.11. PE ratio of stock for trailing 12 months is 28.77, while it has posted earnings per share of $2.45 in the same period. Its PEG reads 3.33 and has Quick Ratio of 3.45 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 2.89% while standing at 3.19% over the month.

Stock’s fiscal year EPS is expected to rise by 1.12% while it is estimated to increase by 12.11% in next year. EPS is likely to grow at an annualized rate of 8.64% for next 5-years, compared to annual growth of -2.36% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stifel on January 30, 2025 offering a Buy rating for the stock and assigned a target price range of between $75 and $90 to it. Coverage by Wolfe Research stated Edwards Lifesciences Corp (EW) stock as an Underperform in their note to investors on January 16, 2025, suggesting a price target of $60 for the stock. On December 16, 2024, BofA Securities Upgrade their recommendations, while on October 11, 2024, Morgan Stanley Resumed their ratings for the stock with a price target of $70. Stock get a Hold rating from Jefferies on September 18, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.